Patrizia Cavazzoni and Peter Marks continue to trumpet the benefits of the US Food and Drug Administration’s hybrid workplace, but a concern lingers that the momentum could lost.
Since the FDA moved to a system allowing most employees to work from home or the office at the beginning...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?